Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript